Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 9.10p 0 05:00:01
Bid Price Offer Price High Price Low Price Open Price
9.00p 9.20p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 6.15 -9.54 3.00 3.0 38.0

Premaitha (NIPT) Latest News

Real-Time news about Premaitha (London Stock Exchange): 0 recent articles
More Premaitha News
Premaitha Takeover Rumours

Premaitha (NIPT) Share Charts

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart

Intraday Premaitha Chart

Intraday Premaitha Chart

Premaitha (NIPT) Discussions and Chat

Premaitha (NIPT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Premaitha trades in real-time

Premaitha (NIPT) Top Chat Posts

DateSubject
12/10/2018
19:22
michaelmouse: LOL. I'll think you'll find my posts were about NIPT until my stalker turned up. I'll leave you with these questions. How much money will they need in the next fund raise? and at what share price? Dilution will be immense making the market cap even more ludicrous. Of course they might not be able to raise the funds, in which case, as it says in the final report, NIPT will go bust. Good luck though.
11/10/2018
06:26
michaelmouse: post 6348 - "Been in the stock market for 20 years and share price movements still baffle me! How is it that such low volumes over the last 3 days alone can cause such dramatic falls in the SP??" Clearly you've not been paying attention then. NIPT has a balance sheet loaded with £12m worth of debt. Imo it's insolvent. They need to raise huge amounts of cash to survive, and we're possibly in a bear market with liquidity rapidly drying up. No buyers only sellers at the moment. 1p on the cards if it survives. Hope that helps. The rest of your post is nonsense. ATB. Aimho of course.
10/10/2018
21:54
ngen yap: Been in the stock market for 20 years and share price movements still baffle me! How is it that such low volumes over the last 3 days alone can cause such dramatic falls in the SP?? Even more intriguing is that we only just got an oversubsribed placing off at 10p. Perhaps we fall back to 10p +/- 0.5p but not this! That's why I try to work on the basis of company fundamentals and mid-to-long term targets. I can see Premaitha are busy recruiting different new roles - always a good sign of growth in a company. Been digesting the settlement news, final results, trading update, placing and most recently new service deal for oncology research. What an amazing string of strong and positive developments. Whatever the truth is regarding the placing, with reference to TW's theories of which I only half believe, we are now below the placing price of 10p. So, private investors who may have felt shafted without being afforded a chance to participate in the placing (including TW) can get in at a discount to that! What is very much overlooked is that the founder owner of Yourgene injected £700k further of his own money, to maintain shareholding at 17%+ - this is a very strong signal. We are doing well. We have eliminated the biggest risk / uncertainty in the business - the Illumina litigation. We are now free to operate globally, and in bed with the two largest NGS provider. We are expanding geographically, and continue to. We are expanding our product offering and most recently into new exciting oncology sector. We have a strong management team with significant options at 10p as incentive. The business is simple. Get as many clinics / labs / bases in as many country as we can using our highly competitive product and with the two largest NGS provider (tick). Expand service offerings in the product offerings - Sage, workflow etc (tick). Increase awareness of NIPT (in progress). Expand into new areas eg oncology (tick). Find more efficiencies to deliver better margins (tick). Once foundations set (point 1), growth can be exponential with points 2, 3 and 4. We are very much underway. Note the eye on Americas - for those who haven't, do read their full glossy FY report in Premaitha website. We recorded 34k volume sales in H1 FY18/19. I expect this to be 80k+ by end FY. I foresee FY18/19 revenue to be circa £9.5-£10.5m, with loss of circa £4m. Cash flow could be smaller depending on capex / R&D. So, recent cash injections x 2 should take us to end March next year based on deals today. Then I expect to see FY19/20 revenue to ramp up to £18m with break even achieved, and for FY20/21, revenue to be £30m (with Illumina entries and new deals / products / categories) and OP of £6-7m. Such growth and towards breakeven / OP would easily justify 30-40p valuation. Key is validating this journey in the months to come. Some questioned previous management report that we are at run rate break even - I think they said on NIPT tests only that we are and I believe so. But add in corporate overheads and other R&D / development costs, hence the overall company loss. Like Adam Reynolds and new CEO, Lynn, I have not been more confident of Premaitha since I invested. See this dip as an opporunity to join those who got in at 10p with a view of 20p soon. My target exit remains at 30-40p! No advice intended. Good luck all.
10/10/2018
16:40
michaelmouse: If this is a bear market then NIPT is in big trouble. A 1p share price would be a good result since they've flagged they need lots more cash. Will they be able to raise any as liquidity diminishes? They'll have to act fast with £12m of debt. Could even go bust. Aimho of course.
30/9/2018
15:06
michaelmouse: IkeaDave - Since you've taken such a strong interest in my blog then try this blog post for size:- hTTp://michae1mouse.blogspot.com/2018/03/a-wolf-in-sheeps-clothing.html BST - the same suspects involved and the same b*llsh*t spoken. Guess what happened to the share price next? ;) Arguably BST were/are in far better financial shape than NIPT. Both set of finances are absolutely dire however. If still in doubt then search for michaelmouse comments on the CPT thread. Guess what? the same suspects and the same outcome. Some undefined vendetta on my part or just stating the facts to help the naïve or less experienced investors from falling for the naughty tricks of the self styled experts? I'll let you decide. Before you do though please, please oh go on please read the rest of my blog ;) As ever AIMHO.
29/9/2018
07:51
michaelmouse: I'd advise that some of you read the report and details of the "proposed placing" more carefully. The fact that they have indicated another massive fund raise is on the cards within 12 months suggests that NIPT's very existence is in doubt. That's the Auditor's comment btw and not just my opinion. Even if they did get an emergency placing away at 10p, at what price the next fund raise? My guess is within the next twelve months the share price could well be below 1p even if the company is still operating? hTTp://michae1mouse.blogspot.com/2018/09/on-brink-of-collapse-what-makes-company.html As ever, AIMHO.
19/9/2018
06:56
multibagger: Posted for future reference: Share price close on 18 Sep 2018 : Mid-price about 12.7p Premaitha Health PLC 19 September 2018 Legal Settlement and Licence Agreement with Illumina Manchester, UK - 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce that the Group has entered into a legal settlement and a licence and supply partnership agreement with Illumina Inc. ("Illumina") (the "Agreements"), resolving the current non-invasive prenatal testing ("NIPT") patent infringement litigation. Key Terms of the Agreements -- Premaitha has taken a licence under Illumina's patent pool for NIPT and is now free to operate in countries where Illumina holds rights to relevant granted patents, including the countries of the European Patent Convention and selected other territories -- Premaitha will develop an IONA(R) test that runs on Illumina sequencing technology, to be launched in early 2020; and within nine months of signing the Agreements has committed to submitting documentation to a notified body for obtaining CE-IVD certification in Europe for the Illumina-compatible IONA(R) test -- Premaitha will work with its customers in the licensed territories to migrate to the IONA(R) test based on Illumina sequencing technology -- Premaitha will make a series of payments in full and final settlement of all ongoing UK litigation. The Directors estimate that these payments will be no more than GBP1m -- Once launched, Premaitha will pay Illumina a royalty per sample tested using the IONA(R) test based on Illumina sequencing technology Lyn Rees, Chief Executive Officer of Premaitha, commented: "These Agreements mark the end of a three and a half year intellectual property dispute and the beginning of a new era whereby the Group, working with Illumina, has the ability to provide NIPT to meet rapidly growing global demand. "Our partnership with Illumina will allow us to move forward and to enter new markets with significant commercial potential. This opens up a much larger addressable market to Premaitha and establishes a new and advanced technological partnership for the IONA(R) test for NIPT. "Notwithstanding the challenges of the past several years, these Agreements represent a significant milestone for the Group, expanding our market potential in partnership with Illumina. Premaitha now has the ability to deliver high quality, customer-service-focused clinical genetic tests to a global community."
17/9/2018
07:35
multibagger: Interesting upward movement in share price - speculation that Illumina legal wrangle is about to be settled. I am not sure that the likes of Illumina settle in a manner that would help the competition ? More likely that NIPT management will be putting out a "we are unaware of a reason for the current share price movement" if this share price rise carries on. Good luck all :)
14/7/2018
10:57
ngen yap: These are share options, so are not free. If directors choose to exercise, they have to pay 7.75p for them and company gets the funds. And assuming share price is above 7.75p, they earn the difference before tax. It is a very good incentivisation tool and I am not surprised (and pleased) they have been awarded, which gives directors added motivation to improve share price above 7.75p.
13/3/2018
22:00
slartybartfaster: The mouse is nailed again by his nemesis, elrico. Caught out in his double standards. elrico 13 Mar '18 - 19:25 - 2106 of 2108 0.000050 3 0 Michaelmouse answered while he still avoids the elephant in the room. MM: Firstly, why does it take them 5 months to prepare relatively simple accounts for the year ending in November 2017? To fill the void, surely they could issue a brief trading statement with guidance on revenues and cash remaining? Most reputable companies don't have a problem with this. Me: 3 months, 5 months, it matters not as long as they fall within the 6 month reporting limit. And you shouldn't use the word "reputable" when invested in frauds (AVN, INTQ) and a company that has restated accounts (TRAKM8). OPTI usually report interims within 4 months and FY 5 months. This info is on the company website, as has been pointed out before. MM:Secondly, by now after announcing a number of agreements they must have some idea about revenues for 2018? Me: Another double standard...lets keep it simple shall we, 7DIG, AVN, TRAKM8, IND, STL; have any of these given revenue guidance for the year ahead? If they have, I missed them. In any event, OPTI is barely 6 months (accounting calendar) into transition from R&D to commercial yet, and many of the partnerships are wrapped up in NDA's, which has attributed to the stagemation thus far. Surely you should be applauding the BOD for not ramping up their book, as so many AIM companies do. In any event, how do you quantify sales in new markets, with new products, using new science? Please explain! MM: Thirdly, the figures are really all that matter presently. At a market cap. of £50m, the potential has already been "baked in" to the share price and has been for two years. The figures they publish still need to justify the current market cap. never mind justify substantial gains in the share price Me: To a degree, I guess I can allow a little leeway with this opinion. However, I would point to the industry valuation for SweetBiotix of £20+m, just 1 of several possible spinouts, and it has no commercial footprint yet, no commercial partner that we know of yet. I would also point out OptiBiotic platform has recently enhanced the LGG strain, the world's most popular probiotic...I'll spare your blushes by not mentioning the value of this strain. OPTI have several strains, which has real potential to be significantly more valuable.....in time. In short, the IP has real value, especially those commercialised via SlimBiome and LP-LDL. MM: Anyway, it's aimho. On a more positive note, if you truly believe in the company and its potential then just hang on in there over the long term, but carefully monitor the figures because ultimately they will drive the share price. The rest is all speculation on what could or might be. Me: Ah, we are aligned. You have long advocated trusting your research and hold long term. And yes of course, one should always monitor what the company says, read between the lines and pay particular attention to companies accounts, especially those that are forced to restate profits as losses....cough, cough! MM: That's all from me for a while. Me: It's probably best, you made a hash of that and I suspect you are perhaps a little concerned the level of partnerships may well prove worthy of rewarding those of use that stand by our research, speak to the company and look at the humanbiome sector and see perhaps what others do not. Don't feel pressured to respond...It's best you don't - keep your head down. ;) http://uk.advfn.com/cmn/fbb/thread.php3?id=35291865&fast_access=1
Premaitha share price data is direct from the London Stock Exchange
Your Recent History
LSE
NIPT
Premaitha
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181211 15:16:23